Portal de Periódicos da CAPES

Reevaluation of the University of Wisconsin 2-Year Protocol for Treating Canine Lymphosarcoma

2007; American Animal Hospital Association; Volume: 43; Issue: 2 Linguagem: Inglês

10.5326/0430085

1547-3317

Claire Inderbinen Kaiser, Janean L. Fidel, Małgorzata Roos, Barbara Kaser‐Hotz,

Infectious Diseases and Mycology

This retrospective study investigated a population of 96 dogs with newly diagnosed malignant lymphosarcoma that were treated with the commonly used University of Wisconsin-Madison (UW-M) chemotherapy protocol. Pretreatment characteristics were analyzed to determine prognostic factors. Dogs with higher World Health Organization (WHO) stages (including stage IV) and dogs with hypercalcemia were at significantly higher risk of relapse (P=0.018 and P=0.016, respectively). Dose reduction, treatment delays, and prior therapy with cortico-steroids were not associated with clinical outcome. First remission duration of 270 days was similar to historically reported data. Overall survival time of 218 days was much shorter than historical data.